Grace Therapeutics Inc. (GRCE)
NASDAQ: GRCE
· Real-Time Price · USD
3.26
0.18 (5.84%)
At close: Aug 15, 2025, 3:59 PM
3.26
0.02%
After-hours: Aug 15, 2025, 04:10 PM EDT
Grace Therapeutics Income Statement
Financials in USD. Fiscal
year is
April - March.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
Revenue | n/a | 8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 2K | n/a | 2K | 2K | 1K | 1K | 1K | 2K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -2K | 5K | -2K | -2K | -1K | -1K | -1K | -2K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -3.09M | -3.18M | -3.7M | -4.83M | -4.96M | -3.26M | -3.04M | -2.09M | -4.45M | -38.07M | -4.25M | -5.11M | -4.73M | -4.4M | -4.47M | -3.57M | -3.15M |
Interest Income | 205K | 167K | 138K | 172K | 235K | 249K | 316K | 212K | 134K | 187K | 67K | 36K | 32K | 114K | 40K | 14K | 20K |
Pretax Income | -3.36M | -382K | -4.76M | -4.28M | -3.34M | -4.05M | -2.6M | -3.72M | -4.31M | -37.96M | -4.16M | -5.08M | -4.77M | -4.55M | -3.78M | 981K | -3.12M |
Net Income | -3.36M | 636K | -4.16M | -3.43M | -2.62M | -3.17M | -2.39M | -3.27M | -4.02M | -29.09M | -3.89M | -4.93M | -4.52M | -3.9M | -3.78M | 981K | -3.12M |
Selling & General & Admin | 2.13M | 1.55M | 1.51M | 1.85M | 2.25M | 1.54M | 1.6M | 1.63M | 1.87M | 2.52M | 1.77M | 1.83M | 2.09M | 2.08M | 2.05M | 2.98M | 2.68M |
Research & Development | 955K | 1.63M | 2.19M | 2.98M | 2.71M | 1.69M | 1.44M | 460K | 1.09M | 1.64M | 2.45M | 3.29M | 2.59M | 2.33M | 2.18M | 585K | 469K |
Other Expenses | n/a | 2K | 1K | 2K | 1K | 35K | n/a | 1K | 1.49M | 33.92M | 20K | -12K | 46K | n/a | 249K | n/a | n/a |
Operating Expenses | 3.09M | 3.18M | 3.7M | 4.83M | 4.96M | 3.26M | 3.04M | 2.09M | 4.45M | 38.07M | 4.25M | 5.11M | 4.73M | 4.4M | 4.47M | 3.57M | 3.15M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 75K | n/a | n/a | n/a | 147K | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | 61K | 30K | n/a | n/a | 51K | 72K | 3K | 10K | 255K | 78K | n/a | n/a |
Cost & Expenses | 3.09M | 3.18M | 3.7M | 4.83M | 4.96M | 3.26M | 3.04M | 2.09M | 4.45M | 38.07M | 4.25M | 5.11M | 4.73M | 4.4M | 4.47M | 3.57M | 3.15M |
Income Tax Expense | n/a | -1.02M | -605K | -852K | -724K | -889K | -208K | -446K | -289K | -8.87M | -274K | -155K | -242K | -648K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 15.92M | 13.72M | 11.51M | 11.51M | 10.93M | 9.18M | 7.49M | 7.55M | 7.44M | 7.44M | 7.43M | 7.42M | 7.39M | 6.76M | 7.38M | 5.46M | 4.34M |
Shares Outstanding (Diluted) | 15.92M | 13.72M | 11.51M | 11.51M | 10.93M | 9.18M | 7.49M | 7.55M | 7.44M | 7.44M | 7.43M | 7.42M | 7.39M | 6.76M | 7.38M | 5.46M | 4.34M |
EPS (Basic) | -0.21 | 0.05 | -0.36 | -0.3 | -0.24 | -0.34 | -0.32 | -0.43 | -0.54 | -3.91 | -0.52 | -0.66 | -0.61 | -0.58 | -0.54 | 0.18 | -0.72 |
EPS (Diluted) | -0.21 | 0.05 | -0.36 | -0.3 | -0.24 | -0.34 | -0.32 | -0.43 | -0.54 | -3.91 | -0.52 | -0.66 | -0.61 | -0.58 | -0.54 | 0.18 | -0.72 |
EBITDA | -3.36M | -3.18M | -3.7M | -4.83M | -4.96M | -4.05M | -3.04M | -2.09M | -2.96M | -4.16M | -4.22M | -5.12M | -4.56M | -4.4M | -4.22M | -3.57M | -3.15M |
EBIT | -3.36M | -3.18M | -3.7M | -4.83M | -4.96M | -3.26M | -3.04M | -2.09M | -2.97M | -4.17M | -4.25M | -5.11M | -4.73M | -4.4M | -4.22M | -3.57M | -3.15M |
Depreciation & Amortization | 2K | 2K | 2K | 2K | 1K | 1K | 1K | 2K | 7K | 8K | 10K | -61K | 167K | n/a | n/a | n/a | n/a |